Professional paper
https://doi.org/10.20471/acc.2022.61.s3.7
Role of Androgen Receptor-Targeted Agents in Localized Prostate Cancer
Jure Murgić
; Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia
Ana Fröbe
; Department of Oncology and Nuclear Medicine, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
Amarnath Challapalli
; University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol BS13NU, UK
Amit Bahl
; University Hospitals Bristol NHS Foundation Trust, Marlborough Street, Bristol BS13NU, UK
Abstract
Anti-androgen therapy continues to be a basic pilar of treatment for both localized
and metastatic prostate cancer. The advent of new generation of androgen receptor targeted agents
(ARTA) transformed the care of patients with advanced disease. After such a success, the steps were
taken to incorporate a new generation of ARTAs into the treatment landscape of localized prostate
cancer. High-risk prostate cancer represents the most aggressive form of localized disease with
significant metastatic potential and poor outcome. Here, the impact of novel therapies will likely
be profound and transforming. This clinical space has already been a showcase for multidisciplinary
treatment where the combination of local therapies with systemic treatment gradually improved patient
outcomes and the chances of cure. The most recent step in redefining the treatment of localized
disease is the adoption of novel ARTAs moving forward the multidisciplinary platform. In this narrative
review, we discuss current clinical evidence supporting the use of novel ARTAs in patients with
localized high-risk prostate cancer and cover recent developments in biomarker-driven strategies for
treatment individualization in this clinical context.
Keywords
Radiotherapy (RT); Prostate Cancer; Androgen Deprivation Therapy (ADT); Abiraterone; Enzalutamide; Androgen Receptor Targeted Agents (ARTAs)
Hrčak ID:
286367
URI
Publication date:
1.10.2022.
Visits: 1.877 *